Search for a command to run...
Promoter shareholding remains stagnant, indicating no insider confidence in growth.
Institutional selling of 1.52% contrasts sharply with sector averages which show no change, indicating potential concerns about Astrazeneca's future performance.
Public participation has increased by 1.09%, but this is often a reactive measure, suggesting lack of conviction in the stock's fundamentals.
| Category | Trend | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|
1Promoter1 | 75% | 75% | 75% | 75% | 75% | 75% | 75% | 75% | |
2Institution6 | 2.35% | 2.57% | 2.88% | 4.44% | 4.35% | 4.32% | 2.92% | 2.92% | |
3Public7 | 8.43% | 7.42% | 7.41% | 5.5% | 5.5% | 5.5% | 6.59% | 6.59% |